VivoSim Labs, Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount
VivoSim Labs, Inc. (VIVS) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount of $2.27 million for the 12-month period ending 2022-03-31, per its 10-K filed 2022-06-10.
Discontinued › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment · last filed 2022-06-10
- VivoSim Labs, Inc. effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2022 was $2.27M, a 30.59% decline from fiscal 2021.
- VivoSim Labs, Inc. effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2021 was $3.27M, a 35.79% decline from fiscal 2020.
- VivoSim Labs, Inc. effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2020 was $5.09M, a 22.06% increase from fiscal 2019.
- VivoSim Labs, Inc. effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2019 was $4.17M.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount 12 month |
|---|---|
| 2022-03-31 | $2.27M 10-K · filed 2022-06-10 |
| 2021-03-31 | $3.27M 10-K · filed 2022-06-10 |
| 2020-03-31 | $5.09M 10-K · filed 2021-06-15 |
| 2019-03-31 | $4.17M 10-K · filed 2020-05-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |